|Articles|June 2, 2023
QualTrak Real-Time PCR and Digital PCR Ecosystem for Streamlined Biologics Development (June 2023)
Author(s)Thermo Fisher Scientific
Biologics—including vaccines, cell and gene therapies, monoclonal antibodies (mAbs), and their biosimilars—have great potential for the treatment and prophylaxis of a broad range of diseases. But, rapid and efficient development of new and effective biologics is no easy feat. With such drastic implications for time and resources, it is imperative that biologic manufacturers choose the right commercial collaborators from the start—agile partners who can improve predictivity, speed, and consistency to bridge basic and clinical research.
Related Content
Trending on Pharmaceutical Technology
1
European Regulators Prepare the Pharma Industry for Future Changes as Legislation is Formalized
2
Shilpa CDMO to Launch as Dedicated Complex Small-Molecule Contract Development and Manufacturing Brand at CPHI Milan
3
Assessment of Silicone Oil Cleaning on Indirect Surfaces in Aseptic Manufacturing
4
Six-Month eCOA Timelines Signal Need for Earlier Planning
5